Alsadi v. Intel Corporation ( 2019 )

1 WO 2 3 4 5 6 IN THE UNITED STATES DISTRICT COURT 7 FOR THE DISTRICT OF ARIZONA 8 9 Ahmad Alsadi and Youssra Lahlou, No. CV-16-03738-PHX-DGC husband and wife, 10 11 Plaintiffs, ORDER 12 vs. 13 Intel Corporation, a Delaware corporation, 14 Defendant. 15 16 17 Defendant Intel Corporation has filed several Daubert motions, a motion to limit 18 the testimony of Plaintiffs’ rebuttal experts, and a motion for summary judgment. 19 Docs. 144-47, 163, 183. The parties also have filed a combined eight motions to strike. 20 Docs. 154-55, 159-61, 167, 187, 200. The motions are fully briefed, and oral argument 21 will not aid in the Court’s decision. See Fed. R. Civ. P. 78(b). For reasons stated below, 22 the Court will grant the Daubert motions in part, grant the motion to limit the testimony of 23 Plaintiffs’ rebuttal experts, deny the motions to strike, and deny summary judgment in part. 24 I. Background. 25 Intel owns an industrial wastewater system (“IWS”) housed in the CH-8 building of 26 its technology development campus in Chandler, Arizona. Technicians at Jones Lange 27 LaSalle (“JLL”) help operate the IWS. Plaintiff Ahmad Alsadi worked for JLL as a HVAC 28 technician at Intel’s Chandler campus. 1 On February 28, 2016, an overdose of the chemical Thio-Red caused the IWS to 2 emit hydrogen sulfide (“H2S”) and potentially other toxic gases. CH-8 and the nearby 3 CN-3 building, where Alsadi was working at the time, were evacuated. Alsadi and other 4 JLL employees were assembled in an area southwest of CH-8. Alsadi began experiencing 5 a tingly throat, cough, headache, and watery eyes. He was evaluated by a nurse and then 6 taken to an urgent care facility for treatment. 7 Plaintiffs filed suit against Intel in September 2016. Doc. 1-2 at 5-8. The second 8 amended complaint asserts negligence and loss of consortium claims. Doc. 20. Plaintiffs 9 allege that as a result of Alsadi’s exposure to toxic gases, he has experienced coughing, 10 pulmonary and respiratory distress, and other injuries requiring medical care. Id. ¶ 21. 11 Alsadi seeks damages for his alleged injuries and future medical care. Id. ¶ 26. He claims 12 that he has reactive airways dysfunction syndrome (“RADS”) which has rendered him 13 permanently disabled. See Docs. 161 at 5, 195 at 3. 14 The case was recently transferred to the undersigned judge with the motions already 15 pending. The Court will summarily deny the motions to strike.1 16 II. Intel’s Daubert Motions. 17 A. Rule 702 and Daubert. 18 Intel seeks to exclude expert testimony under Federal Rule of Evidence 702 19 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 597 (1993). Under Rule 20 702, an expert may offer “scientific, technical, or other specialized knowledge” if it “will 21 assist the trier of fact to understand the evidence,” provided the testimony rests on 22 23 1 Plaintiffs move to strike the Daubert motions, claiming that they essentially are 24 motions in limine limited to three pages with no reply brief under Local Rule of Civil Procedure 7.2. See Docs. 159-61 at 2-4. Judges in this district, including the undersigned 25 judge, generally do not consider Daubert motions to be motions in limine. Moreover, Plaintiffs stipulated to the filing of reply briefs. Doc. 152 at 2. Plaintiffs complain that 26 Intel did not meet and confer with them before filing the motions (citing LRCiv 7.2(l)), but this clearly would not have changed the briefing as shown by Plaintiffs’ opposition to the 27 motions. Plaintiffs’ motions to strike the Daubert motions will be denied. 28 1 “sufficient facts or data” and “reliable principles and methods,” and “the witness has 2 reliably applied the principles and methods to the facts of the case.” Fed. R. Evid. 3 702(a)-(d). The proponent of expert testimony has the ultimate burden of showing, by a 4 preponderance of the evidence, that the proposed testimony is admissible under Rule 702. 5 See Cooper v. Brown, 510 F.3d 870, 942 (9th Cir. 2007); Fed. R. Evid. 104(a). The trial 6 court acts as a gatekeeper for expert testimony to assure that it “both rests on a reliable 7 foundation and is relevant to the task at hand.” Daubert, 509 U.S. at 597. 8 Plaintiffs emphasize the statement in Daubert that a district court should conduct 9 the admissibility analysis with a “liberal thrust” favoring admission. Doc. 161 at 6; see 10 Daubert, 509 U.S. at 588. The Court will follow this guidance, but with the understanding 11 that the Court may admit expert opinions only if it can determine that Plaintiffs have shown 12 each of the Rule 702 requirements to be satisfied by a preponderance of the evidence. See 13 Fed. R. Evid. 104(a); Daubert, 509 U.S. at 592 & n.10; Bourjaily v. United States, 483 U.S. 14 171, 175-76 (1987).2 15 B. Intel’s Motion to Exclude Opinions of Dr. Anselmo Garcia. 16 Dr. Anselmo Garcia is a pulmonologist with Arizona Chest and Sleep Medicine. 17 He began treating Alsadi in March 2016. He prepared a two-and-a-half page letter, dated 18 April 23, 2017, in which he reviews Alsadi’s medical treatment and reaches certain 19 conclusions as to Alsadi’s diagnosis, the cause of his injuries, and his prognosis. Doc. 20 148-4 at 2-4. In July 2017, Plaintiffs disclosed Dr. Garcia as an expert to testify about: 21 (1) Alsadi’s history, examinations, treatments, tests, findings, diagnosis, and prognosis, 22 including the permanent nature of his injuries; (2) the reasonableness of the treatments and 23 their costs; (3) the cause of Alsadi’s injuries; and (4) the opinions expressed in the April 23 24 “letter report.” Docs. 148-3 at 123, 161 at 7-8. 25 26 2 Plaintiffs request a Daubert hearing in passing, but they do not explain what would be done at the hearing, and their responses to Defendants’ motions set forth a complete 27 explanation of their position, including citations to many sources in support of their experts’ opinions. In light of the full briefing provided by both sides, the Court concludes 28 that a Daubert hearing is not necessary. 1 Intel argues that Dr. Garcia should be precluded from offering his causation 2 opinions because the opinions fail to meet Rule 702’s requirements for admissibility. 3 Doc. 145 at 1-3. The Court agrees.3 4 In his April 23 letter, Dr. Garcia states that exposure to H2S can cause the following 5 injuries and symptoms: 6 In low levels of exposure there can be irritation to the eyes, nose, and throat. 7 Exposure, even at relatively low concentrations can cause painful dermatitis and burning of the eyes. In the respiratory tract, exposure can lead to 8 immediate or delayed pulmonary edema. Pulmonary manifestations at low 9 concentrations [of] 50 ppm can cause cough, shortness of breath, and bronchial or lung hemorrhage. Long term irritation with cough and 10 bronchospasm can be a complication. At higher concentrations bronchitis 11 and pulmonary edema can develop. Due to severe dyspnea and edema individuals can develop cyanosis and . . . severe exposure can lead to death. 12 13 Doc. 148-4 at 3. 14 Dr. Garcia does not provide the basis for these general causation opinions. He cites 15 no medical literature or independent research concerning the effects of H2S exposure, and 16 he describes no clinical experience he may have treating patients exposed to H2S. Nor does 17 he identify the principles and methods he used to reach his conclusions.4 18 With respect to the specific cause of Alsadi’s injuries, Dr. Garcia states that, “as a 19 result his exposure, [Alsadi] has recurrent exacerbations with severe bouts of shortness of 20 breath and cough limiting his ability to work and complete his activities of daily living.” 21 Id. at 3-4. Dr. Garcia further states that Alsadi “will continue to suffer from recurrent 22 23 3 Intel further argues that Dr. Garcia should be precluded from offering his prognosis 24 opinion that Alsadi is at risk for lung disease and a possible lung transplant in the future. Id. Plaintiffs have withdrawn this opinion. Doc. 161 at 3, 18. 25 4 Plaintiffs cite the definition of RADS provided by the National Center for 26 Biotechnology Information (“NCBI”), which includes exposure to H2S. Doc. 161 at 11. Although Dr. Garcia referenced the NCBI definition of RADS in his deposition to describe 27 the purported differences between RADS and reactive airway disease (Doc. 161-2 at 84), his letter does not state that he relied on the definition in reaching his causation opinions 28 in this case. 1 reactive airway disease requiring ongoing long term therapy and he may develop further 2 complications from this injury[,] including worsening shortness of breath, pulmonary 3 fibrosis, persistent cough with a chance of progressive lung injury where [o]xygen therapy 4 may be needed.” Id. at 4.5 Again, however, Dr. Garcia does not provide a basis for these 5 conclusions. 6 Under Rule 702, an expert must explain the basis for his conclusions in a manner 7 that allows the Court to determine whether he is using reliable principles and methods and 8 is applying them to the facts of the case in a reliable manner. Fed. R. Evid. 702(c)-(d). 9 The gap between foundational facts and the expert’s conclusions cannot be bridged merely 10 by the mere ipse dixit – the say-so – of the expert. Gen. Elec. Co. v. Joiner, 522 U.S. 136, 11 146 (1997). By his own admissions, Dr. Garcia offers nothing more than ipse dixit. 12 In his deposition, Dr. Garcia described his role in this case and the purpose of his 13 April 23 letter as follows: 14 When I was asked to do this, it was never to write an expert report. It was 15 simply to write my understanding of Mr. Alsadi’s current condition while I was taking care of him and my concerns as to his overall care and where he 16 was at. 17 So to say I wrote an expert report, I don’t know if I’d say I went through and 18 tried to do all of the literature search that I would normally do and so forth. I simply wrote him a letter as his treating physician and what my concerns 19 were at the time. . . . 20 I was never told you are an expert witness, . . . or please write down your 21 expert report, because it would have been a much more comprehensive 22 statement than a two-and-a-half page to whom it may concern, thank you very much kind of thing. 23 24 Doc. 148-3 at 102. 25 26 27 5 Dr. Garcia considers reactive airways disease and RADS to be the same condition. 28 See Doc. 148-3 at 118. 1 Dr. Garcia also confirmed that while he was Alsadi’s treating physician, he is not a 2 medical or legal expert witness in this case. Id. at 103, 106. In fact, Dr. Garcia was 3 “completely taken by surprise” to learn that he had been disclosed as an expert witness 4 given assurances from Alsadi’s counsel that he would “never need to testify or be part of 5 this [case].” Id. at 106. Dr. Garcia made clear that he would not be comfortable telling a 6 jury, from a medical or legal standpoint, that Alsadi’s injuries were caused by exposure to 7 H2S because he would first “have to do a lot more review, and that’s not something [he’s] 8 ever been asked to do.” Id. at 107. 9 As a treating physician, Dr. Garcia was not required to produce an expert report 10 under Rule 26(a)(2)(B). See Fed. R. Civ. P. 26(a)(2)(B). If Plaintiffs intended to call him 11 to testify about his treatment of Alsadi, they instead were required to disclose only “the 12 subject matter on which the witness is expected to present evidence under Rule 702” and 13 “a summary of the facts and opinions to which the witness is expected to testify.” Fed. R. 14 Civ. P. 26(a)(2)(C). 15 Dr. Garcia was excused from the more detailed report requirement, however, only 16 if his testimony was limited to opinions he formed during the course of his treatment of 17 Alsadi. If Plaintiffs intended to have him present opinions developed beyond the course 18 of treatment, then a Rule 26(a)(2)(B) report was required for those additional opinions. See 19 Goodman v. Staples The Office Superstore, LLC, 644 F.3d 817 (9th Cir. 2011). That report 20 must include a complete statement of the testimony Dr. Garcia would provide at trial on 21 the additional opinions, as well as the basis and reasons for those opinions. Fed. R. Civ. P. 22 26(a)(2)(B). Plaintiffs produced no such report. The two-page letter written by Dr. Garcia 23 does not comply with the requirements of Rule 26(a)(2)(B), and Plaintiffs emphasize 24 repeatedly in their response to the Daubert motion that he is testifying only as a treating 25 physician. Given the requirements of Rule 26, the limited nature of Dr. Garcia’s letter, and 26 the Ninth Circuit’s decision in Goodman, Dr. Garcia will not be permitted at trial to give 27 28 opinions beyond those formed during the course of his treatment of Alsadi. As noted 1 above, Dr. Garcia testified in his deposition that those treatment-related opinions do not 2 include the research, analysis, or testing designed to determine the precise cause of Alsadi’s 3 condition.6 4 Plaintiffs assert that Dr. Garcia’s investigation of Alsadi’s medical condition and its 5 cause has been in furtherance of Alsadi’s treatment, and that Dr. Garcia used the word 6 “causation” not in the “medical/legal” sense, but as a treating doctor. Doc. 161 at 7-8 7 (citing Doc. 161-2 at 10). But this does not change the fact that any testimony Dr. Garcia 8 might give about the cause of Alsadi’s injuries would be expert opinion under Rule 702. 9 His “causation opinion is an expert opinion under [Rule] 702 because it requires training, 10 education, and specialized knowledge.” Alfaro v. D. Las Vegas, Inc., No. 2:15-CV-02190- 11 MMD-PAL, 2016 WL 4473421, at *10 (D. Nev. Aug. 24, 2016); see United States v. 12 Urena, 659 F.3d 903, 908 (9th Cir. 2011) (agreeing with the Second and Eleventh Circuits 13 that “a physician’s assessment of the cause of an injury is expert testimony”); Gyrodata 14 Inc. v. Atl. Inertial Sys. Inc., No. CV-08-7897-GHK (FMOx), 2011 WL 13116732, at *3 15 (C.D. Cal. Oct. 11, 2011) (treating doctor “opinions fall within Rule 702 when they are 16 used to explain the causation of that condition”); Anderson v. Hess Corp., 592 F. Supp. 2d 17 1174, 1178 (D.N.D. 2009) (“A treating physician’s expert opinion on causation is subject 18 to the same standards of scientific reliability that govern the expert opinions of physicians 19 hired solely for purposes of litigation.”). 20 Plaintiffs further assert that the factual basis of an expert opinion goes to the 21 credibility of the testimony, not its admissibility. Doc. 161 at 8. But Intel does not merely 22 challenge the factual basis for Dr. Garcia’s opinions; Intel also argues that the opinions are 23 not the product of reliable principles and methods. The requirements of Rule 702 – 24 including that the opinion be supported by an adequate factual basis – are conditions for 25 26 6 For this reason, the many scientific sources cited by Plaintiffs in their response to 27 the Daubert motion are inapposite. Those sources were not considered by Dr. Garcia, were not cited in a Rule 26(a)(2)(B) report, and Plaintiffs cannot rely on them as the basis for 28 his opinion in this case. 1 admissibility, and the Supreme Court has made clear that the “trial judge must determine 2 at the outset, pursuant to Rule 104(a),” whether the expert’s testimony is admissible under 3 Rule 702. Daubert, 509 U.S. at 592. 4 Plaintiffs’ reliance on D’Agnese v. Novartis Pharmaceuticals Corp., No. CV-12- 5 00749-PHX-JAT, 2013 WL 321773 (D. Ariz. Jan. 28, 2013), is misplaced. Doc. 161 6 at 8-9. No Daubert hearing was needed in that case because it was unclear whether the 7 experts actually intended to offer causation opinions. D’Agnese, 2013 WL 321773, at *3. 8 The court was “concerned that a ruling based on opinions that are not actually being offered 9 by these witnesses would be an opinion on an issue that is not ripe and would be advisory.” 10 Id. at *3 n.2. Although Plaintiffs have withdrawn Dr. Garcia’s opinion that Alsadi is at 11 risk for lung disease and may need a lung transplant in the future (Doc. 161 at 5, 18), they 12 continue to assert that Dr. Garcia should be permitted to opine that RADS “was a product 13 of [Alsadi’s] toxic inhalation on Intel’s campus” (id. at 5). This case is not like D’Agnese. 14 Plaintiffs argue that Dr. Garcia is a board-certified pulmonologist and, based on his 15 treatment of Alsadi, he is “firm in his well-founded opinion that exposure to [H2S] caused 16 RADS.” Doc. 161 at 14-15. But the mere fact that Dr. Garcia is a qualified pulmonologist 17 who treated Alsadi does not render his opinions on causation admissible under Rule 702 18 and Daubert. See Daubert v. Merrell Dow Pharm., Inc., 43 F.3d 1311, 1319 (9th Cir. 19 1995) (“We’ve been presented with only the experts’ qualifications, their conclusions and 20 their assurances of reliability. Under Daubert, that’s not enough.”). 21 Plaintiffs assert that Dr. Garcia “did not equivocate” in his causation opinions. 22 Doc. 161 at 14. But a lack of equivocation does not satisfy the requirements of Rule 702, 23 and Dr. Garcia made clear in his deposition that he did not do the work necessary to state 24 causation opinions under that rule. Doc. 161-2 at 4. 25 Plaintiffs contend that Dr. Garcia’s specific causation opinion is reliable because it 26 is based on a differential diagnosis. Doc. 161 at 16-18. But the first step in a proper 27 differential diagnosis “is to compile a comprehensive list of hypotheses that might explain 28 the set of salient clinical findings under consideration.” Clausen v. M/V NEW CARISSA, 1 339 F.3d 1049, 1057 (9th Cir. 2003). “The issue at this point in the process is which of the 2 competing causes are generally capable of causing the patient’s symptoms or mortality. 3 Expert testimony that rules in a potential cause that is not so capable is unreliable.” Id. 4 at 1057-58 (emphasis in original). In addition to the fact that Dr. Garcia does not describe 5 the process or basis for any differential diagnosis in his letter, he does not first show that 6 H2S is capable of causing RADS. See id.; Hall v. Baxter Healthcare Corp., 947 F. Supp. 7 1387, 1413 (D. Or. 1996) (“[I]t is . . . important to recognize that a fundamental assumption 8 underlying [differential diagnosis] is that the final, suspected ‘cause’ . . . must actually be 9 capable of causing the injury.”). 10 Nor have Plaintiffs shown that Dr. Garcia actually performed a proper differential 11 diagnosis. To perform such a diagnosis, Dr. Garcia must identify “all of the potential 12 hypotheses that might explain [Alsadi’s] symptoms, [and] must then engage in a process 13 of elimination, eliminating hypotheses on the basis of a continuing examination of the 14 evidence so as to reach a conclusion as to the most likely cause of the findings in [this] 15 case.” Clausen, 339 F.3d at 1058. Dr. Garcia “must provide reasons for rejecting 16 alternative hypotheses ‘using scientific methods and procedures’ and the elimination of 17 those hypotheses must be founded on more than ‘subjective beliefs or unsupported 18 speculation.’” Id. (quoting Claar v. Burlington N. R.R. Co., 29 F.3d 499, 502 (9th Cir. 19 1994)). 20 Dr. Garcia acknowledged that Alsadi’s symptoms could be caused by various 21 medical conditions. Doc. 161-2 at 39. In his April 23 letter, Dr. Garcia identified a host 22 of conditions – allergies, acid reflux, neurogenic cough, acute infection, and vocal cord 23 abnormality – that potentially could cause Alsadi’s symptoms. Doc. 148-4 at 2-3. But 24 instead of ruling out these conditions, Dr. Garcia continued Alsadi on therapy for them. Id. 25 at 2; see Goodwin v. Danek Med., Inc., No. CV-S-95-433-HDM(RJJ), 1999 WL 1117007, 26 at *2 (D. Nev. July 8, 1999) (“There is no evidence that Dr. Yarus undertook any 27 differential diagnosis to eliminate other possible causes of Goodwin’s pain. His opinion is 28 1 based solely on the fact that Goodwin had screws implanted and that there was pain. Such 2 reasoning has been rejected in other cases.”) (citations omitted).7 3 In summary, Plaintiffs have not shown by a preponderance of the evidence that 4 Dr. Garcia’s causation opinions are based on sufficient facts or data to which reliable 5 principles and methods have been applied reliably. The causation opinions therefore are 6 not admissible under Rule 702(b)-(d).8 7 C. Intel’s Motion to Exclude Opinions of Dr. Charles Landers. 8 Dr. Landers is board-certified in internal, pulmonary, and critical care medicine. He 9 works with the Chest Medicine and Critical Care Medical Group. He has privileges at 10 Sharp Memorial Hospital in San Diego. Doc. 148-4 at 14. 11 Dr. Landers prepared a rebuttal report dated February 22, 2008. Id. at 13-41. He 12 opines in part that Alsadi had a significant exposure to H2S and other toxic gases at the 13 Intel campus and developed RADS. Id. at 35-36. Intel argues that Dr. Landers’s causation 14 opinion is inadmissible under Rule 702 because it based not on reliable scientific principles 15 and methods, but rather on the timing of the exposure and onset of symptoms. Doc. 146 16 at 3, 6-13. Intel further argues that Dr. Landers’s diagnosis of RADS is not based on a 17 reliable methodology. Id. at 13-16.9 18 1. Causation Opinion. 19 Dr. Landers reviewed Alsadi’s medical records, reports of Intel’s experts and 20 independent medical evaluators, Intel’s emergency response plans, a material safety sheet 21 22 7 Plaintiffs’ citation to Anderson is inapposite. Doc. 161 at 17. The medical expert 23 in that case “ruled out other possible causes of [the plaintiff’s] symptoms,” and his differential diagnosis “was for the purpose of identifying not only [the plaintiff’s] 24 condition, but also the cause of that condition.” Anderson, 592 F. Supp. 2d at 1183. 25 8 As noted, Plaintiffs have withdrawn Dr. Garcia’s prognosis opinion that Alsadi is at risk for lung disease and a possible lung transplant in the future. See Doc. 161 at 3, 18. 26 Dr. Garcia therefore is precluded from offering this opinion at trial. 27 9 Intel moves to preclude Dr. Landers from testifying about Alsadi’s prognosis (id. at 1), but presents no supporting argument. The Court will deny the motion in this 28 respect. 1 for Thio-Red, and certain discovery materials. Doc. 148-4 at 13-14. He provides a 2 thorough account of Alsadi’s medical history in his rebuttal report. Id. at 14-35. He then 3 offers these opinions (id. at 35): 4 • Alsadi had a significant exposure to toxic industrial gases on 2/28/16. 5 The information is compatible with Thio Red, H2S and possibly other toxic gases. 6 7 • Alsadi develop[ed] RADS thereafter and continues to suffer from [shortness of breath], cough, wheezing and external limitations, 8 despite ongoing therapy. 9 10 Dr. Landers concludes that, as a result of his exposure to toxic gases at the Intel campus, 11 Alsadi “has experienced extensive resulting changes including[] RADS[.]” Id. at 36. 12 Dr. Landers does not explain the basis for this conclusion. Although his Rule 13 26(a)(2)(B) report includes a lengthy account of Alsadi’s medical history and symptoms, 14 Dr. Landers does not bridge the gap between these foundational facts and his causation 15 opinion with any reliable principle or method. His opinion that Alsadi’s exposure to toxic 16 gases caused RADS is nothing more than unvarnished ipse dixit.10 17 In his deposition, Dr. Landers relied on the temporal proximity between the 18 exposure and Alsadi’s symptoms, claiming that it is not a mere coincidence that Alsadi was 19 exposed to toxic gases and thereafter developed RADS: 20 I think that RADS from toxic industrial gas exposure is the best fit for the 21 data that we have about Mr. Alsadi from day one to now. I think the information is compatible with Thio-Red[,] hydrogen sulfite[,] and other 22 toxic gases, unknown amount, unknown duration, unknown mix of multiple gases. I think . . . the information that we have is that’s the best fit. I don’t 23 think it’s a coincidence. I think he got exposed to gases, and now he’s 24 disabled. 25 26 27 10 Dr. Landers interviewed Alsadi via Facetime and the interview notes are attached to his report (see id. at 35, 43-47), but he does not explain how the notes support his 28 opinions. 1 Id. at 57; see also id. at 55 (“This is not a coincidence that suddenly on the 28th of February 2 [Alsadi] . . . got short of breath[.] This is not a coincidence that he developed asthma out 3 of the blue in the setting of this. This is the cause.”). 4 “It is well settled that a causation opinion based solely on a temporal relationship is 5 not derived from the scientific method and is therefore insufficient to satisfy the 6 requirements of [Rule] 702.” Cartwright v. Home Depot U.S.A., Inc., 936 F. Supp. 900, 7 906 (M.D. Fla. 1996) (quoting Federal Judicial Center’s Reference Manual on Scientific 8 Evidence); see Daubert, 43 F.3d at 1319 (excluding opinion that Bendectin caused the 9 plaintiffs’ birth defects where the expert relied on “the timing of their mothers’ ingestion 10 of the drug”); Moore v. Ashland Chem. Inc., 151 F.3d 269, 279 (5th Cir. 1998) (the district 11 court was “correct in viewing with skepticism [the expert’s] reliance on the temporal 12 proximity between the exposure and injury”); Porter v. Whitehall Labs., Inc., 9 F.3d 607, 13 611 (7th Cir. 1993) (causation opinions properly excluded where they were based “merely 14 on the temporal relationship between the ingestion of ibuprofen and the injury”); Lassalle 15 v. McNeilus Truck & Mfg., Inc., No. 16-CV-00766-WHO, 2017 WL 3115141, at *5 (N.D. 16 Cal. July 21, 2017) (excluding causation opinion where the “temporal connection between 17 the events made up [the expert’s] mind that a purported explosion event caused the 18 decedent’s eventual brain death”); Prall v. Ford Motor Co., No. 2:14-CV-001313-MMD- 19 GWF, 2017 WL 361545, at *4 (D. Nev. Jan. 24, 2017) (“[The expert] concludes that the 20 existence of one event after the existence of another is sufficient to prove the first event 21 caused the second. This is a logical fallacy – post hoc ergo propter hoc. While the 22 existence of the [throttle] problem is necessary to conclude that it was the cause of the 23 accident, it is not, in itself, sufficient to establish causation.”). 24 Plaintiffs note that testimony about a doctor’s own clinical experiences is not mere 25 speculation. Doc. 160 at 9. But Dr. Landers does not rely on his own clinical experience 26 in forming his causation opinion. He has never treated a patient exposed to H2S. See 27 Doc. 148-4 at 50-53. 28 1 Plaintiffs assert that Dr. Landers’s causation opinion is grounded in the “sound 2 application of the principles and methodology of his discipline.” Doc. 160 at 8. But no 3 specific principles are identified. Id. Plaintiffs do claim that Dr. Landers performed a 4 differential diagnosis to determine causation by “consider[ing] numerous variables, 5 including the details of the exposure, the temporal relationship between exposure and 6 symptom onset, the symptoms themselves, the correlation with those typically associated 7 with RADS, the lack of preexisting conditions, and the lack of alternative explanations.” 8 Doc. 160 at 9. But Plaintiffs cite no portion of Dr. Landers’s report to support this 9 assertion, nor do they explain how Dr. Landers’s purported consideration of the numerous 10 variables led him to conclude that the exposure event caused RADS. Dr. Landers himself 11 does not claim to have performed a differential diagnosis to establish causation, and, as 12 explained above, he does not sufficiently bridge the analytical gap between the medical 13 history recounted in his report and his conclusion that the exposure event caused RADS. 14 Under Rule 702 and Daubert, the proponent of expert scientific testimony “must 15 explain precisely how [the expert] went about reaching [his] conclusions[.]” Daubert, 43 16 F.3d at 1319. Plaintiffs provide no such explanation for Dr. Landers’s causation opinion. 17 Instead, Plaintiffs rely entirely on “unadorned assertions that the methodology [he] 18 employed comports with standard scientific procedures.” Id. Rule 702 and Daubert 19 require more. See id.; Moore, 151 F.3d at 279 (affirming the district court’s finding that 20 “the ‘analytical gap’ between [the expert’s] causation opinion and the scientific knowledge 21 and available data advanced to support that opinion was too wide”); Cartwright, 936 F. 22 Supp. at 906 (excluding opinion where the expert “fail[ed] to identify what ‘methodology’ 23 he did employ, other than reliance on the sequence of events”). 24 Plaintiffs have not shown by a preponderance of the evidence that Dr. Landers’s 25 causation opinion is based on reliable principles and methods applied reliably to the facts 26 of this case. The opinion therefore is not admissible under Rule 702(c)-(d). 27 2. Diagnosis Opinion. 28 Dr. Landers describes RADS and the treatment it requires as follows: 1 [RADS] is asthma resulting from a single exposure to a high concentration of irritant agents or a repeated exposure to moderate to low levels of irritant 2 agents. The asthma developed in RADS is new. It is not immune mediated. 3 (see attached Chapter from Up to Date: [RADS] and Irritant Induced Asthma). 4 5 RADS may resolve with treatment or become chronic and require long term treatment for asthma or bronchial hyperactivity. The asthma treatments 6 would be the same as other types of asthma. Inhaled anti-inflammatory drugs 7 are used as “controllers” with inhaled steroids. Inhaled long acting bronchodilators help minimize symptoms. Short acting rescue inhalers can 8 help quickly reduce chest tightness and bronchospasms. 9 Doc. 148-4 at 16. 10 As noted, Dr. Landers discusses Alsadi’s medical history at length. He starts this 11 discussion by explaining that Alsadi was a healthy man without respiratory symptoms or 12 asthma prior to the exposure event. Id. at 14. Dr. Landers then describes Alsadi’s 13 continuing treatment with Dr. Garcia and other medical providers for shortness of breath, 14 wheezing, chronic cough, bronchospasms, and chest pain. Id. at 14-35. Dr. Landers also 15 offers rebuttal opinions challenging the opinions of Intel’s experts that Alsadi does not 16 suffer from RADS. Id. at 29-39. Dr. Landers ultimately concludes that, based upon the 17 two years of persistent cough, wheezing, and other asthma-related symptoms, it is highly 18 likely that Alsadi has RADS. Id. at 17. He notes that this was the diagnosis of Alsadi’s 19 treating physician, Dr. Garcia, and that he agrees with Dr. Garcia’s overall assessment and 20 treatment of Alsadi. Id. at 17, 37. 21 Intel does not dispute that Dr. Landers is qualified to diagnose an individual with 22 RADS. Nor does Intel contend that he relied on insufficient facts and data to reach his 23 diagnosis. Instead, Intel relies on opinions of its own expert, Dr. Gerald Schwartzberg, to 24 argue that Dr. Landers’s methodology suffers from four deficiencies. Doc. 146 at 14. 25 First, Intel contends that there is no evidence that Alsadi was exposed to high levels 26 of toxic gas. Id. Dr. Landers, according to Intel, assumed that Alsadi was exposed to a 27 28 higher level of H2S than the 11.7 ppm measured nearly an hour after the release. Id. But 1 Intel does not explain why any such assumption would be unreasonable in this case, 2 particularly when there was no constant, real-time monitoring of H2S levels during the 3 exposure event. 4 Second, Intel criticizes Dr. Landers for accepting Alsadi’s representation that he had 5 no respiratory problems before the exposure. Id. at 14-15. But self-reported patient 6 histories “provide information upon which physicians may, and at times must, rely in their 7 diagnostic work.” Todd v. Baker, No. CV 10-127-M-DWM, 2012 WL 1999629, at *3 (D. 8 Mont. June 4, 2012) (citations omitted). Intel will be free to challenge the credibility of 9 Alsadi’s self-reported medical history through cross-examination and rebuttal evidence. 10 See id. 11 Third, Intel contends that Dr. Landers misinterpreted Alsadi’s pulmonary function 12 tests (“PFTs”). Id. at 15. Intel claims that Dr. Landers “fixated” on the results of a single 13 PFT and failed to consider the effect of Alsadi’s weight and effort level. Id. Dr. Landers 14 and Dr. Schwartzberg clearly disagree as to the results of Alsadi’s PFTs (see Doc. 160-8 15 at 12), but this is no basis for excluding Dr. Landers’s diagnosis. 16 Fourth, Intel contends that Dr. Landers’s methodology is deficient because he 17 performed no methacholine challenge test. Doc. 146 at 16. Intel claims that such tests are 18 routinely used to diagnose RADS. Id. Dr. Landers agrees that the test could confirm a 19 RADS diagnosis, but explains that it is not appropriate to subject a patient with abnormal 20 pulmonary functions to the potential hazard of doing a methacholine challenge. Doc. 160-8 21 at 130. Intel does not address this point in its briefing. 22 Given Dr. Landers’s scientific knowledge, training, and experience as a board- 23 certified pulmonologist, and his extensive review of Alsadi’s medical history and ongoing 24 symptoms, Plaintiffs have shown that his diagnosis of RADS is sufficiently reliable to be 25 admissible under Rule 702. Doc. 160 at 6, 13-6. Intel’s criticisms of his diagnosis may be 26 appropriate subjects for cross-examination, rebuttal expert testimony, and jury argument, 27 but they do not so undercut Dr. Landers’s opinion as to render it inadmissible under 28 Rule 702. Intel’s motion to exclude will be denied in this regard. 1 D. Intel’s Motion to Exclude the Opinions of Dr. Kelly Johnson-Arbor. 2 Dr. Johnson-Arbor is board-certified in emergency medicine and toxicology. She 3 is the attending physician for the toxicology clinic at MedStar Georgetown University 4 Hospital. She teaches toxicology at Georgetown University and the Connecticut Poison 5 Control Center. Doc. 148-4 at 65. 6 Plaintiffs retained Dr. Johnson-Arbor to address the significance of Alsadi’s 7 exposure to H2S on February 28, 2016, the peak H2S concentration of 11.7 ppm that was 8 measured in the CH-8 building on that date, and the possible health effects of such an 9 exposure. Id. at 66. She prepared a rebuttal report dated March 14, 2018. Id. at 65-68. 10 She opines that Alsadi was exposed to concentrations of H2S higher than 11.7 ppm, he has 11 RADS, and his exposure to H2S caused his RADs. Id. at 67. Intel argues that each of these 12 opinions is inadmissible under Rule 702 and Daubert. Doc. 147. The Court agrees. 13 1. Exposure Opinion. 14 Dr. Johnson-Arbor acknowledges that it is impossible to determine the exact 15 concentration of H2S to which Alsadi was exposed on the date of the incident. Doc. 148-4 16 at 66. She concludes, however, that because “the H2S concentration of 11.7 ppm was 17 measured more than 45 minutes after the noxious odor was first reported and well after the 18 first reports of symptomatic patients, this measurement more likely than not represents an 19 inaccurate reflection of the H2S concentrations[.]” Id. at 67. 20 In her deposition, Dr. Johnson-Arbor explained that the concentration of gas to 21 which a person will be exposed depends on “many factors,” including where the person is 22 located in relation to the exposure’s source and wind directions. Doc. 148-3 at 70. She 23 acknowledged, however, that she does not know exactly where Alsadi was exposed to H2S 24 on the Intel campus and did not focus on where the exposure happened in reaching her 25 opinion. Id. at 69; see Doc. 159-6 at 11-13. She further stated that she has done only 26 informal research on how gases migrate. Doc. 148-3 at 70. 27 Intel argues that Dr. Johnson-Arbor’s exposure opinion is inadmissible because she 28 is not qualified to opine on the flow of gases and knows nothing about the “many factors” 1 in this case relevant to Alsadi’s exposure to H2S. Doc. 147 at 10-11. Plaintiffs do not 2 address this argument in their response. 3 Dr. Johnson-Arbor asserts that because mucous membrane irritation occurs at H2S 4 concentrations of 50 ppm, Alsadi was likely exposed to a higher concentration of H2S than 5 the reported peak of 11.7 ppm. Doc. 148-4 at 66-67. But she cites no medical literature or 6 other scientific basis for the proposition that mucous membrane irritation occurs at H2S 7 concentrations of 50 ppm.11 8 Plaintiffs have not shown by a preponderance of the evidence that Dr. Johnson- 9 Arbor is qualified to opine that Alsadi likely was exposed to concentrations of H2S higher 10 than 11.7 ppm, or that this opinion is based on sufficient facts or data to which reliable 11 principles and methods have been applied reliably. The opinion therefore is not admissible 12 under Rule 702. 13 2. Diagnosis Opinion. 14 Dr. Johnson-Arbor opines that Alsadi likely has RADS, not reactive airways 15 disease. Doc. 148-4 at 67. She notes that exposures to significant concentrations of H2S 16 have been “associated with the development of [RADS]” and that Alsadi’s symptoms and 17 medical treatment are “consistent with a diagnosis of RADS[.]” Id. see Doc. 148-3 at 75. 18 But merely stating that RADS is associated with high levels of H2S and consistent with 19 Alsadi’s symptoms is not sufficient to support a medical diagnosis of RADS under 20 Rule 702. See Kolesar v. United Agri Prods., Inc., 412 F. Supp. 2d 686, 698 (W.D. Mich. 21 2006) (expert’s opinion that the plaintiff’s symptoms were “consistent with” RADS was 22 properly excluded under Rule 702). 23 Moreover, by her own admissions, Dr. Johnson-Arbor is not qualified to diagnose 24 RADS. She does not recall ever treating a patient with RADS. Doc. 148-3 at 56. She 25 repeatedly declined to answer questions about RADS in her deposition because she is not 26 27 11 Intel contends that no evidence suggests that Alsadi actually experienced mucous membrane irritation. Doc. 147 at 10. But as Dr. Johnson-Arbor notes, Alsadi complained 28 of a cough and sore throat at the time of the exposure. Docs. 148-3 at 71, 148-4 at 65. 1 a pulmonologist. Id. at 54, 67, 72, 76. She was unable to describe the differences between 2 RADS and reactive airway disease. Id. at 55. She could offer no opinion on the treatment 3 for RADS, or whether obese people have more asthmatic conditions, because these issues 4 were outside her area of expertise. Id. at 59, 72. When asked about the differing opinions 5 on the results of Alsadi’s PFTs, she “defer[red] those discussion to the pulmonary experts.” 6 Id. at 60; see id. at 75. She reiterated her opinion that Alsadi’s symptoms “appear to be 7 suggestive of RADS,” but made clear that “[a] pulmonologist should review the records to 8 definitively establish this diagnosis.” Id. at 73. 9 Plaintiffs assert that Dr. Johnson-Arbor is qualified to diagnose RADS, but present 10 no argument or evidence to support this assertion. Doc. 159 at 18. Instead, Plaintiffs “have 11 opted to rely on an expert pulmonologist in order to avoid this very dispute.” Id.; see 12 Doc. 195 at 15 n.4. The Court will exclude Dr. Johnson-Arbor’s opinion that Alsadi has 13 RADS.12 14 3. Causation Opinion. 15 Dr. Johnson-Arbor opines that the exposure event “was temporally connected and 16 directly responsible for [Alsadi’s] subsequent diagnosis of pulmonary disease consistent 17 with RADS.” Doc. 148-3 at 67. The sole basis for this opinion is “[t]he fact that he had a 18 chemical exposure, the fact that he was presumably healthy before that exposure, and then 19 after the exposure he developed wheezing and asthma-like conditions.” Doc. 148-3 at 58. 20 But as explained above, an expert’s causation opinion based solely on a temporal 21 relationship is not derived from the scientific method and therefore is insufficient to satisfy 22 the requirements of Rule 702. Cartwright, 936 F. Supp. at 906; see Moore, 151 F.3d at 278 23 (excluding causation opinion based solely on “the relatively short time between Moore’s 24 exposure to the chemicals and the onset of [RADS]”). 25 26 12 Plaintiffs contend that Dr. Johnson-Arbor may rely on Dr. Landers’s diagnosis of RADS. Id. Although Dr. Johnson-Arbor could rely on opinions of other experts in 27 reaching her own conclusions, she would not be permitted to parrot the opinions of other experts or to vouch for those experts. See In re Bard IVC Filters Prods. Liab. Litig., No. 28 MDL 15-02641-PHX DGC, 2017 WL 6554163, at *2 (D. Ariz. Dec. 22, 2017). 1 Dr. Johnson-Arbor provides no basis for her causation opinion other than a temporal 2 relationship. When asked how the exposure event caused Alsadi to develop RADS, she 3 stated (Doc. 148-3 at 67): 4 I’m not a pulmonologist. I am not an immunologist or anyone that studies 5 the path of physiology of RADS so I would not want to even attempt to describe to you the physiological process that are involved in the 6 development of RADS[.] 7 Plaintiffs contend that the causation opinion is based on a differential diagnosis. 8 Doc. 159 at 11. But Plaintiffs do not explain how any such differential diagnosis would be 9 reliable given that Dr. Johnson-Arbor is not qualified to diagnose RADS. Moreover, Dr. 10 Johnson-Arbor performed no differential diagnosis in this case. She recognized that to 11 establish a diagnosis of RADS, other similar conditions must be considered and eliminated, 12 and this differential diagnosis “could include, but would not be limited to[,] RADS, 13 reactive airways disease, vocal cord disfunction, [and] GERD.” Doc. 159-6 at 6; see 14 Doc. 148-4 at 67. But she only considered RADS and did not rule out the other conditions. 15 Plaintiffs have not shown by a preponderance of the evidence that Dr. Johnson- 16 Arbor is qualified to render a causation opinion in this case or that her causation opinion is 17 reliable. The opinion therefore is not admissible under Rule 702.13 18 D. Intel’s Motion to Exclude the Opinions of Greg Gerganoff. 19 1. Gerganoff’s Qualifications. 20 Generally speaking, Gerganoff opines that Intel failed to reasonably safeguard 21 workers from a known hazardous condition and the failure caused Alsadi’s injuries. See 22 Doc. 180 at 13. Intel contends that Gerganoff is not qualified to render any such opinions 23 because the opinions are not based on science and Gerganoff is not a medical doctor, 24 chemist, engineer, or industrial hygienist. Doc. 163 at 3-7. 25 26 27 13 Intel’s motion to strike (Doc. 167) the new causation opinions in Dr. Johnson- 28 Arbor’s declaration (see Doc. 159-2) is denied as moot given the ruling above. 1 Rule 702 “contemplates a broad conception of expert qualifications.” Thomas v. 2 Newton Int’l Enters., 42 F.3d 1266, 1269 (9th Cir. 1994). “As the terms of the rule state, 3 an expert may be qualified either by ‘knowledge, skill, experience, training, or education.’” 4 Id. 5 Gerganoff is a work-place safety expert whose opinions are based on his technical 6 knowledge, training, and experience. See Doc. 164-3. He is a certified safety professional 7 with 18 years of safety experience in the fields of manufacturing, construction, and oil and 8 gas. Id. at 2-5. He is a member of the American Society of Safety Engineers. Id. at 4. He 9 has operated his own consulting and expert witness firm, Rocky Mountain Safety 10 Consulting, since 2014. Id. at 2. The mere fact that Gerganoff is not a doctor, scientist, 11 engineer, or industrial hygienist does not make him unqualified to render safety opinions 12 in this case. See Thomas, 42 F.3d at 1269 (district court erred in excluding expert testimony 13 concerning safety conditions on a ship during the loading process where the witness had 14 more than 20 years of experience as a longshoreman).14 15 Intel contends that Gerganoff is not qualified to interpret and apply OSHA standards 16 to the facts of this case because he has never worked for OSHA, has never reported safety 17 violations to OSHA, and has never worked or served as a consultant for an industrial waste 18 treatment or semi-conductor manufacturing plant. Doc. 163 at 11. But Gerganoff has 19 worked with OSHA during jobsite safety inspections and is an authorized OSHA trainer. 20 Doc. 164-3 at 2-4. He has provided safety training on H2S. Doc. 164-4 at 2. The Court 21 finds that Gerganoff is qualified to provide testimony concerning relevant OSHA 22 standards. 23 2. Gerganoff’s Opinions. 24 Gerganoff prepared a 17-page expert report. Doc. 164-4. The report includes a 25 statement of Gerganoff’s qualifications, the bases for his opinions, and a summary of 26 27 14 Gerganoff does not purport to provide opinions from a scientific perspective, but 28 only from a safety standpoint. See Doc. 163 at 5 n.2, 8. 1 relevant facts. Id. at 2-4. His opinions in this case are set forth in seven separate sections 2 of the report. Id. at 4-16. 3 Intel contends that certain opinions offered by Gerganoff in section two of his report 4 are inadmissible because they are factually incorrect and otherwise based on Gerganoff’s 5 misunderstanding of the facts. Doc. 163 at 10-15. To support their respective arguments, 6 each side sets forth its version of the events surrounding the H2S exposure at the Intel 7 campus. See Doc. 163 at 3-4 (citing Doc. 145 at 3-6); Doc. 180 at 3-9. Many facts are 8 genuinely disputed. See id. The Court cannot conclude on the present record that the 9 opinions Gerganoff offers in section two of his report are based on insufficient facts and 10 data. See Fed. R. Evid. 702(b). The Court will not grant the motion to exclude on this 11 point. The parties can address their factual disagreements at trial, and Intel can object to 12 any expert testimony it believes is inadmissible under Rule 702. 13 The Ninth Circuit has recognized that “safety standards such as those contained in 14 OSHA assist ‘a jury’s determination of negligence because they represent the community’s 15 judgment as to what conduct is reasonable and what conduct is not.’” Cooper v. Firestone 16 Tire & Rubber Co., 945 F.2d 1103, 1107 (9th Cir. 1991) (citations omitted). Consistent 17 with this authority, the Arizona Court of Appeals has held that “an OSHA standard may be 18 considered as some evidence of the standard of care even when OSHA requirements are 19 not binding on the defendant, so long as there is sufficient foundation (1) establishing that 20 the standard at issue is directly related to the exercise of reasonable care and (2) a 21 reasonable nexus exists between the proffered standard and the circumstances of the 22 injury.” Wendland v. AdobeAir, Inc., 21 P.3d 390, 396 (Ariz. Ct. App. 2009). 23 Based in large part on the testimony of its rebuttal expert, Marshall Krotenberg 24 (Doc. 165), Intel contends that Gerganoff’s OSHA-based opinions set forth in sections 25 three through seven of his report are inadmissible under Wendland because he misinterprets 26 and misapplies OSHA standards (Doc. 163 at 15-17). But Gerganoff is not required to 27 accept Intel’s interpretation of the standards, and the Court cannot conclude on the present 28 record that each of Gerganoff’s OSHA-based opinions is admissible. Intel will be free to 1 cross-examine Gerganoff at trial and to object on the basis of relevancy, foundation, 2 Rule 403, or other grounds. The Court will rule on objections as they are made. Intel’s 3 motion to exclude Gerganoff’s opinions will be denied.15 4 III. Intel’s Motion to Limit the Testimony of Plaintiffs’ Rebuttal Experts. 5 Intel moves to preclude Plaintiffs from presenting testimony of their rebuttal experts 6 – Dr. Johnson-Arbor, Dr. Landers, and Derrick Denis – in Plaintiffs’ case-in-chief or in 7 opposition to Intel’s summary judgment motion, which does not rely on testimony of 8 Intel’s experts. Doc. 144. The Court will grant the motion. 9 The scheduling order in this case specifically limited rebuttal experts to “responding 10 to opinions stated by initial experts.” Doc. 10 at 3. As other courts have recognized, “[t]he 11 principal objective of rebuttal is to permit a litigant to counter new, unforeseen facts 12 brought out in the other side’s case.” Marmo v. Tyson Fresh Meats, Inc., 457 F.3d 748, 13 759 (8th Cir. 2006). “As such, rebuttal evidence may be used to challenge the evidence or 14 theory of an opponent – and not to establish a case-in-chief.” Id.; see Ellis v. Corizon, Inc., 15 No. 1:15-CV-00304-BLW, 2018 WL 6268199, at *5 (D. Idaho Nov. 30, 2018) (precluding 16 the plaintiff’s rebuttal expert from testifying in the case-in-chief and noting that if 17 defendants decided not to present their experts at trial, the plaintiff would be foreclosed 18 from putting his rebuttal expert on the stand); Danganan v. Am. Family Mut. Ins., No. 2:17- 19 CV-02786-RFB-PAL, 2018 WL 3660198, at *4 (D. Nev. Aug. 2, 2018) (same); Kirksey v. 20 Schindler Elevator Corp., No. CV 15-0115-WS-N, 2016 WL 5213928, at *17 (S.D. Ala. 21 Sept. 21, 2016) (same); Palm Capital, LLC v. Travelers Prop. Cas. Co. of Am., No. CV- 22 15-6385-DMG (PJWx), 2017 WL 5665010, at *2 (C.D. Cal. Apr. 3, 2017) (holding that 23 the plaintiff would “be limited to using its rebuttal experts for just that – rebuttal – and may 24 not call upon them to testify in its case-in-chief”); Grove City Veterinary Serv., LLC v. 25 26 15 Intel’s motions to strike Gerganoff’s newly disclosed opinion and rebuttal report (Docs. 155, 187) are denied because the late disclosure of expert opinions is not a proper 27 basis for a motion to strike under Local Rule 7.2(m). Plaintiffs, however, will be limited to presenting only those opinions of Gerganoff that were timely disclosed. See Fed. R. 28 Civ. P. 37(c)(1). Intel can object at trial to untimely opinions. 1 Charter Practices, Int’l LLC, No. 3:13-CV-2276-AC, 2016 WL 1573830, at *16 (D. Or. 2 Apr. 19, 2016) (explaining that rebuttal testimony is not “an opportunity for the correction 3 of any oversights in the plaintiff’s case in chief”) (citation omitted); Sharma v. City of 4 Vancouver, No. C06-5688BHS, 2008 WL 11343467, at *2 (W.D. Wash. June 17, 2008) 5 (“Until and unless Defendants’ experts testify, Plaintiff’s experts will be unable, as a 6 practical matter, to truly rebut such testimony. Therefore, Plaintiff’s rebuttal experts will 7 be allowed to testify at trial only after Defendants’ experts have testified.”); Santiago v. 8 Select Portfolio Servicing, Inc., No. CV07-262-S-EJL, 2008 WL 4411392, at *5 (D. Idaho 9 Sept. 25, 2008) (“Plaintiff will not be allowed to . . . use the rebuttal expert in her case-in- 10 chief, instead, such an expert witness, if any, shall only be called as a rebuttal witness.”); 11 Int’l Bus. Machines Corp. v. Fasco Indus., Inc., No. C-93-20326 RPA, 1995 WL 115421, 12 at *3 (N.D. Cal. Mar. 15, 1995) (“[A] party can control the scope of the testimony of its 13 adversary’s rebuttal experts by limiting its own experts’ testimony to a given subject 14 matter. A party who forgoes designating experts on the initial disclosure date will thus 15 find itself in a purely reactive mode, greatly restricted in its ability to offer expert 16 testimony.”). 17 For the same reason, district courts are “not required to consider rebuttal expert 18 reports from a non-moving party at the summary judgment phase.” Ellis, 2018 WL 19 6268199, at *4. “Rule 56 motions are designed to test the sufficiency of the non-moving 20 party’s case-in-chief, and weed out cases which cannot be successfully presented at trial[,] 21 . . . and the “purpose of Rule 56 is best served by only considering evidence which the 22 non-moving party could properly submit as part of its case-in-chief.” Id.; see Daggett v. 23 United States, No. 08-21026-CIV, 2010 WL 11553196, at *1 (S.D. Fla. Feb. 4, 2010) (“the 24 plaintiffs cannot rely on experts designated solely as rebuttal experts in their case-in-chief 25 to try to avoid summary judgment”); Waste Servs., Inc. v. Waste Mgmt., Inc., No. 06-320, 26 2006 WL 5109230 at *1 (M.D. Fla. Dec. 1, 2006) (disallowing testimony of rebuttal expert 27 on matters on which the plaintiff has the burden of proof at trial). 28 1 Plaintiffs do not address this legal authority. Instead, they cite this Court’s ruling 2 in Bernal v. Daewoo Motor America, Inc., No. CV09-1502-PHX-DGC, 2011 WL 3 13183093, at *2 (D. Ariz. Aug. 31, 2011), precluding the plaintiffs from presenting rebuttal 4 experts in their case-in-chief. Doc. 162 at 14. Plaintiffs claim that the issue in Bernal was 5 whether the plaintiffs’ experts “were first disclosed only as rebuttal witnesses in response 6 to defense experts.” Id. at 14-15. Plaintiffs assert that the ruling in Bernal should not apply 7 in this case because Intel has been allowed to retain experts to counter Plaintiffs’ rebuttal 8 experts. Id. at 15. 9 The issue in Bernal was whether the plaintiff should be precluded from calling 10 defense experts during the plaintiffs’ case-in-chief, to be followed by testimony from the 11 plaintiffs’ rebuttal experts. 2011 WL 13183093, at *2. The defendant argued that “such 12 a tactic would allow the plaintiffs to get their rebuttal experts into their case-in-chief 13 through a ‘back door’ technique” that was inconsistent with the Court’s case management 14 order. Id. The Court concluded that “[p]ermitting the[] rebuttal experts to testify during 15 [the plaintiffs’] case in chief would not be fair when the defense experts have not been 16 permitted to state the full opinions that are being rebutted.” Id. The Court further 17 concluded: 18 [T]he fairest result is to hold the parties to the order in which they chose to 19 disclose their experts. Plaintiffs will be permitted to present the experts they disclosed in initial reports during their case in chief, Defendants will be 20 permitted to present defense experts during their case in chief, and Plaintiffs 21 will be permitted to present their rebuttal experts during their rebuttal case. Plaintiffs will not be permitted to call their rebuttal experts during their case 22 in chief. 23 Id. The Court reaches the same conclusion in this case.16 24 25 26 16 Plaintiffs’ reliance on AZ Holding, L.L.C. v. Frederick, No. CV-08-0276-PHX- 27 LOA, 2009 WL 2432745 (D. Ariz. Aug. 10, 2009), is misplaced because that case involved the imposition of sanctions under Rule 37. Plaintiffs’ citation to Eitel v. McCool, 782 F.2d 28 1470 (9th Cir. 1986), fares no better as the case involved a motion for default judgment. 1 Plaintiffs acknowledge that the sequence at trial is consistent with the order of expert 2 disclosures: “the plaintiff’s case-in-chief is followed by the defendant’s case, and the 3 plaintiff is then permitted to present a rebuttal case.” Doc. 162 at 3. Plaintiffs assert that 4 this sequence is not appropriate because Intel has engaged in “questionable litigation 5 tactics” by “flipping” Dr. Schwartzberg, which purportedly had a “crescendo effect” on the 6 timing and nature of expert disclosures. Id. at 3-5. But the record does not support this 7 assertion. 8 Plaintiffs complain that Intel had the “last word” with its medical causation experts. 9 Id. at 3. Plaintiffs incorrectly assert that Intel sought to extend the deadline for disclosing 10 rebuttal experts, and Plaintiffs agreed to stagger the deadlines which gave Intel additional 11 time to respond to Plaintiffs’ causation experts. Id. at 4. In fact, Plaintiffs sought the 12 extension because Dr. Johnson-Arbor “was not able to complete her expert rebuttal report” 13 by the deadline. Doc. 53 at 2. 14 Plaintiffs further assert that Intel flipped Dr. Schwartzberg after Plaintiffs had 15 disclosed him to say that the exposure event caused Alsadi’s injuries. Doc. 162 at 3, 6. 16 But Plaintiffs did not disclose Dr. Schwartzberg as an expert in this case. See Doc. 161-1. 17 Instead, Plaintiffs disclosed Dr. Garcia as their sole causation expert. Id. at 3. The fact 18 that Dr. Garcia’s causation opinions are inadmissible, and Dr. Schwartzberg now believes 19 that the exposure event could not have caused RADS, is no basis for allowing Plaintiffs to 20 present rebuttal experts in their case-in-chief. 21 Plaintiffs have provided no factual or legal basis to present their rebuttal experts in 22 their case-in-chief at trial or in opposition to Intel’s summary judgment motion. The Court 23 will grant Intel’s motion to limit the testimony of Plaintiffs’ rebuttal experts to Plaintiff’s 24 rebuttal case at trial.17 25 26 17 Plaintiffs move to strike Intel’s motion because “it is clear that Intel is seeking summary judgment relief, [and] summary judgment procedural and substantive rules 27 apply.” Doc. 154 at 1. No such relief is sought in Intel’s motion. Instead, Intel has filed a separate summary judgment motion to which Plaintiffs have responded fully. Docs. 183, 28 195. Plaintiff’s motion to strike will be denied. 1 IV. Intel’s Motion for Summary Judgment. 2 A. Summary Judgment Standard. 3 Summary judgment is appropriate if the moving party shows that there is no genuine 4 dispute as to any material fact and the movant is entitled to judgment as a matter of law. 5 Fed. R. Civ. P. 56(a). Only disputes over facts that might affect the outcome of the suit 6 will preclude summary judgment, and the disputed evidence must be “such that a 7 reasonable jury could return a verdict for the nonmoving party.” Anderson v. Liberty 8 Lobby, Inc., 477 U.S. 242, 248 (1986). The evidence must be viewed in the light most 9 favorable to the nonmoving party, Matsushita Elec. Indus. Co. v. Zenith Radio Corp., 475 10 U.S. 574, 587 (1986), and all justifiable inferences are drawn in that party’s favor because 11 “[c]redibility determinations, the weighing of evidence, and the drawing of inferences from 12 the facts are jury functions,” Anderson, 477 U.S. at 255. 13 B. Discussion. 14 To establish his negligence claim, Alsadi must prove (1) a duty requiring Intel to 15 conform to a certain standard of care, (2) a breach of that duty by Intel, (3) a causal 16 connection between Intel’s breach and Alsadi’s injuries, and (4) actual damages. See 17 Gipson v. Kasey, 150 P.3d 228, 230 (Ariz. 2007). Intel contends that summary judgment 18 is warranted because Intel owed no duty of care to Alsadi and he cannot show that Intel 19 breached any standard of care or caused his injuries. Doc. 183 at 3-14. 20 1. Duty. 21 Duty is an “obligation, recognized by law, which requires the defendant to conform 22 to a particular standard of conduct in order to protect others against unreasonable risks of 23 harm.” Gipson, 150 P.3d at 230 (citation omitted). “[D]uty in Arizona is based on either 24 recognized common law special relationships or relationships created by public policy.” 25 Quiroz v. ALCOA Inc., 416 P.3d 824, 829 (Ariz. 2018) (citing Gipson, 150 P.3d at 231- 26 32). “Duties based on special relationships may arise from several sources, including 27 special relationships recognized by the common law, contracts, or ‘conduct undertaken by 28 the defendant.’” Id. (quoting Gipson, 150 P.3d at 232). 1 The issue in this case is whether a special relationship existed between Alsadi and 2 Intel that gave rise to a legal duty. Intel owns the Chandler campus, including the CH-8 3 building that houses the IWS. Doc. 196-3 at 6. Alsadi worked on the Chandler campus 4 as an employee of JLL, not Intel. Intel notes, correctly, that an Arizona landowner 5 generally “owes no non-delegable duty to the injured employee of a contractor . . . to 6 provide a safe work place.” Rause v. Paperchine, Inc., 743 F. Supp. 2d 1114, 1122 (D. 7 Ariz. 2010); see Lee v. M & H Enters., Inc., 347 P.3d 1153, 1159 (Ariz. Ct. App. 2015) 8 (“Wal-Mart, as the landowner, did not owe Lee a non-delegable duty of care . . . because 9 he was working as an employee of an independent contractor at the time he sustained 10 injuries.”) (citing Welker v. Kennecott, 403 P.2d 330, 339 (1965)); see also Doc. 151 at 7-8. 11 Alsadi argues that Intel is liable for his injuries under Restatement (Second) of Torts 12 § 414 (1965) because Intel retained some control over JLL’s work. Docs. 117 at 9-11, 195 13 at 6-10. “Restatement § 414 addresses the direct liability of a landowner based on a theory 14 of retained control: 15 One who entrusts work to an independent contractor, but who retains the 16 control of any part of the work, is subject to liability for physical harm to others for whose safety the [landowner] owes a duty to exercise reasonable 17 care, which is caused by his failure to exercise his control with reasonable 18 care. 19 To trigger liability under Restatement § 414, a landowner ‘must have retained some 20 measure of control not over the premises of the work site, but over the actual work 21 performed.’” Lee, 347 P.3d at 1159 (quoting Lewis v. N.J. Riebe Enters., Inc., 825 P.2d 5, 22 11 (Ariz. 1992)). 23 Intel contends that JLL operates the IWS and Intel retains no direct control over the 24 specific manner in which the work is done. Doc. 183 at 5-6 (citing Pruett v. Precision 25 Plumbing, Inc., 554 P.2d 655, 658-59 (Ariz. 1976)). In Pruett, the Arizona Supreme Court 26 relied on comment (c) to § 414 in holding that the landowner could not be held liable where 27 it controlled neither the method nor the details of the contractor’s work. 554 P.2d 28 at 658-59. The court later made clear in Lewis, however, that “[c]omment (c) does not say 1 that a [landowner] must control the day-to-day details of a contractor’s work in order to be 2 subject to liability under § 414.” 825 P.2d at 12 (emphasis in original). Instead, comment 3 (c) merely provides that the landowner “must have retained at least some degree of control 4 over the manner in which the work is done[,]” such as “a retention of a right of supervision 5 that the contractor is not entirely free to do the work in his own way.” Restatement § 414, 6 cmt. (c). “[T]he appropriate test for retained control is found in comment (a) to § 414, 7 which states that a [landowner] . . . may be liable under [§ 414] unless he exercises his 8 supervisory control with reasonable care so as to prevent the work which he has ordered to 9 be done from causing injury to others.” Lewis, 825 P.2d at 12. 10 According to Intel, no jury reasonably could find that Intel retained sufficient 11 control over JLL’s work to be held liable under § 414. Doc. 183 at 6-10. The Court does 12 not agree. 13 Scott Graunke, Intel’s environmental health and safety manager, testified that Intel 14 controls the mixture of chemicals used in the IWS, and JLL merely follows Intel’s 15 instructions. Doc. 196-3 at 14-15; see Doc. 159-13 ¶ 21. Graunke stated that H2S is a 16 known IWS byproduct, and Intel controls the amount of H2S in the ambient air through 17 various control systems Intel has in place, including direct exhaust, scrubbed exhaust, and 18 general building room ventilation. Doc. 196-3 at 3-4. When Intel receives a health and 19 safety complaint concerning a potential toxic emission, Intel will “err on the side of caution 20 and . . . shut the area down if at all possible.” Id. at 8. From this evidence, a reasonable 21 jury could find that Intel retained at least “some measure of control” over JLL’s operation 22 of the IWS and H2S emissions. Lewis, 825 P.2d at 11. 23 Graunke and Robbie McGill, Intel’s safety program manager, testified that when a 24 chemical release occurs, Intel’s emergency response team (“ERT”) is responsible for 25 making sure that all on the Chandler campus, including JLL employees, are directed out of 26 the hazard zone and to an appropriate assembly point according to Intel’s evacuation plans. 27 Id. at 10-11; Doc. 196-6 at 5-6, 31. John McDonald, Intel’s ERT leader, expects both Intel 28 employees and contractors to follow his directions concerning evacuation assembly points. 1 Doc. 196-4 at 12. John Blood, one of Intel’s manufacturing shift managers, explained that 2 the ERT helps ensure that JLL employees perform their jobs safely. Doc. 196-5 at 7-8; see 3 also Doc. 196-1 at 23. The failure to follow ERT’s instructions can result in disciplinary 4 action, including termination. Doc. 196-6 at 31; see Doc. 196-8 at 4. 5 A jury reasonably could find from this evidence that Intel “assume[d] affirmative 6 duties with respect to [the] safety” of JLL employees – including Alsadi – and “retaine[d] 7 sufficient control to be held liable under § 414 for the negligent exercise of its safety 8 responsibilities.” Lewis, 825 P.2d at 12. Intel asserts that it exercised no control over the 9 evacuation and emergency response to the exposure event (Doc. 199 at 6-7), but this goes 10 to whether Intel breached its safety responsibilities, not whether it had assumed those 11 duties. 12 Intel further asserts that Plaintiffs have failed to create a triable issue as to whether 13 Intel retained control over JLL’s work based on the contract between Intel and JLL. 14 Doc. 199 at 3-4. Contractual provisions may be relevant to the retained control 15 determination, but they are not necessarily dispositive. See Lewis, 825 P.2d at 11. 16 Moreover, McDonald confirmed that the contract between Intel and JLL required JLL 17 employees to follow the directions given by Intel’s ERT personnel and to comply with Intel 18 safety standards. Doc. 196-3 at 6-9. Whether the contract supports a finding of retained 19 control will be for the jury to decide.18 20 The issue of retained control under § 414 generally is “a question of fact which 21 ordinarily should be left to the fact finder.” Lewis, 825 P.2d at 11 (emphasis in original); 22 see Lee, 347 P.3d at 1159. Construing the evidence in Plaintiffs’ favor, a jury reasonably 23 could find that Intel retained some control over the work that allegedly caused Alsadi’s 24 25 18 Intel objects to McDonald’s testimony about the contractual provisions for lack of foundation, noting that Plaintiffs have not produced the contract. Doc. 199 at 4 & n.3. 26 But a nonmoving party need not “produce evidence in a form that would be admissible at trial in order to avoid summary judgment.” Orr v. Bank of Am., 285 F.3d 764, 774 (9th 27 Cir. 2002). Plaintiffs may be able to lay sufficient foundation for McDonald’s testimony at trial, and the contract itself could be admissible as a business record under Federal Rule 28 of Evidence 803(6). See United States v. Childs, 5 F.3d 1328, 133-34 (9th Cir. 1993). 1 injuries. The Court will not grant summary judgment on the duty element of Alsadi’s 2 negligence claim. See Rause, 743 F. Supp. at 1132 (finding a triable issue as to whether a 3 papermill’s owner retained sufficient control over the work of a contractor to impose 4 liability under § 414 where the owner had supervisors walking around the mill engaged in 5 safety inspections and the supervisors had the right to correct any unsafe practices they 6 observed); Lewis, 825 P.2d at 13 (the “negligent exercise of a right to prohibit or correct a 7 subcontractor’s unsafe work practice . . . impose[s] liability [under § 414] for an unsafe 8 condition created by a subcontractor which injures an employee of that subcontractor”); 9 see also Doc. 151 at 8-9. 10 2. Breach. 11 “Whether the defendant has met the standard of care – that is, whether there has 12 been a breach of duty – is an issue of fact that turns on the specifics of the individual case.” 13 Gipson, 150 P.3d at 230. As noted, Plaintiffs disclosed Gerganoff to testify that Intel 14 violated certain industry standards and thereby created an unsafe work environment. See 15 Doc. 180 at 13. Intel asserts that summary judgment would be warranted if the Court were 16 to grant Intel’s Daubert motion challenging Gerganoff’s opinions (Doc. 183 at 10), but for 17 reasons stated above, the Daubert motion will be denied. The Court therefore will deny 18 summary judgment on breach of the standard of care. 19 3. Causation. 20 In Arizona, “[t]he proximate cause of an injury is that which, in a natural and 21 continuous sequence, unbroken by any efficient intervening cause, produces an injury, and 22 without which the injury would not have occurred.” Coulbourn v. Air & Liquid Sys. Corp., 23 No. CV-13-08141-PCT-SRB, 2015 WL 12656236, at *2 (D. Ariz. Feb. 11, 2015) (quoting 24 McDowell v. Davis, 448 P.2d 869, 871 (Ariz. 1968)). “Causation is generally a question 25 of fact for the jury[.]” Id. (quoting Barrett v. Harris, 86 P.3d 954, 958 (Ariz. Ct. App. 26 2004)). Only where the plaintiffs’ evidence “does not establish a causal connection, 27 leaving causation to the jury’s speculation,’ should the court remove this question from the 28 1 jury.” Benshoof v. Nat’l Gypsum Co., 978 F.2d 475, 476 (9th Cir. 1992) (quoting 2 Robertson v. Sixpence Inns of Am., Inc., 789 P.2d 1040, 1047 (Ariz. 1990)). 3 Intel contends that expert medical testimony is required to prove causation because 4 an inference of a causal link between Alsadi’s exposure to H2S and his injuries is beyond 5 a layperson’s common knowledge. Doc. 183 at 10-11. Intel relies on this statement in 6 Crystal Coca-Cola Bottling Co. v. Cathey, 317 P.2d 1094, 1100 (Ariz. 1957): 7 “Ordinarily[,] a jury would require expert medical evidence to help it to determine whether 8 an illness resulted from particular acts.” Doc. 183 at 11. But “[t]he soundness of this 9 proposition depends upon the nature of the illness with which the jury is concerned.” 317 10 P.2d at 1100.19 11 Plaintiffs argue that a layperson reasonably could infer from the evidence that 12 Alsadi’s exposure to H2S caused an injury, and summary judgment on causation is 13 therefore not appropriate. Doc. 195 at 12. The Court agrees in part, and will require further 14 briefing on remaining issues as described below. 15 The following facts are not genuinely disputed for purposes of summary judgment. 16 On February 28, 2016, the IWS released H2S. Doc. 184 ¶¶ 1, 13-14, 39. Alsadi was 17 working nearby when the release occurred. Id. ¶ 15. He was evacuated to a designated 18 assembly point directly across from the CH-8 building, where the IWS is housed, and 19 smelled a strong “rotten egg” odor during the evacuation. Id. ¶¶ 23-29. He began 20 experiencing a tingly throat, light cough, and headache, and reported these symptoms to 21 McDonald. Id. ¶¶ 32, 35. McDonald noticed that Alsadi had very glossy and watery eyes. 22 23 19 The other cases Intel cites are inapposite. See Ryan v. San Francisco Peaks Trucking Co., 262 P.3d 863, 870 (Ariz. Ct. App. 2011) (expert testimony required in 24 medical malpractice cases under A.R.S. § 12-563); W. Bonded Prods. v. Indus. Comm’n of Ariz., 647 P.2d 657, 658 (Ariz. Ct. App. 1982) (expert testimony required in workers’ 25 compensation cases where the result of the industrial accident is not apparent); Claar v. Burlington N. R.R. Co., 29 F.3d 499, 504 (9th Cir. 1994) (affirming summary judgment on 26 Federal Employer’s Liability Act claims where the plaintiffs presented “no evidence that workplace exposure to chemicals played any part, no matter how small, in causing their 27 injuries”); Rhodes v. Energy Marine LLC, No. CV-14-08206-PCT-JJT, 2016 WL 6700973, at *4 (D. Ariz. Nov. 15, 2016) (requiring expert testimony on the cause of an explosion 28 because the explosion “[did] not speak for itself”). 1 Doc. 196-4 at 19-20. Two other JLL employees reported similar symptoms. Id.; Doc. 184 2 ¶ 36. Alsadi and his coworkers were evaluated by a nurse and then taken to an urgent care 3 facility for treatment. Doc. 184 ¶¶ 37-38. 4 Alsadi states that he had no significant health history or respiratory problems when 5 he arrived at work on the night in question. Doc. 197-1 ¶ 36. As noted, he smelled a rotten 6 egg odor during the evacuation and immediately began experiencing physical symptoms. 7 Gerganoff states in his report that H2S is an inhalation hazard that has a rotten egg odor. 8 Doc. 164-4 at 2.20 9 Accepting this evidence as true, a jury reasonably could find, without the benefit of 10 expert medical testimony, that Alsadi was exposed to H2S and the exposure caused a toxic 11 inhalation injury. See Cathey, 317 P.2d at 1100 (“[A] reasonable person does not require 12 the aid of expert medical evidence in order to determine that the discovery of a fly in a 13 mouthful of Coca-Cola caused the vomiting which immediately followed the 14 discovery.”).21 The Court will deny summary judgment to the extent Intel argues that the 15 evidence does not support a finding that Intel caused Alsadi any injury. 16 Intel contends that even if it were apparent to a layperson that the H2S exposure 17 caused Alsadi’s initial symptoms, those same symptoms cannot be bootstrapped into proof 18 that the exposure caused RADS. Docs. 183 at 11-12, 199 at 7-11. In its reply brief, Intel 19 cites several cases requiring expert testimony to show that a chemical exposure caused 20 21 20 Intel challenges some of Gerganoff’s opinions, as discussed above, but does not dispute that H2S is a hazardous gas that smells like rotten eggs. See 40 C.F.R. pt. 355 (EPA 22 regulation listing H2S as an “extremely hazardous substance”); St. Bernard Citizens For Envtl. Quality, Inc. v. Chalmette Ref., L.L.C., 399 F. Supp. 2d 726, 737 n.5 (E.D. La. 2005) 23 (noting that H2S is a “hazardous gas[] with a pungent odor often described as similar to rotten eggs”) (citing 40 C.F.R. pt. 355); see also U.S. Department of Labor, OSHA, 24 https://www.osha.gov/SLTC/hydrogensulfide/hazards.html (stating that the rotten egg odor from H2S is first noticeable at 0.01-1.5 ppm) (last visited Sept. 20, 2019). 25 21 Such a finding by the jury would be consistent with the testimony of Dr. Steven 26 Pike, one of Intel’s medical experts. Dr. Pike testified that even at low concentrations, H2S can cause cough and throat irritation. Doc. 196-12 at 3. He further stated that eye irritation 27 is one of the best indicators of H2S above 50 ppm. Id. He opined in his initial report that Alsadi “most probably suffered an inhalation injury that lasted no less than 24 hours and 28 likely up to at least a week[.]” Id. at 4. 1 RADS. Doc. 199 at 8 (citing Higgins v. Koch Dev. Corp., 794 F.3d 697, 702 (7th Cir. 2 2015) (affirming summary judgment where the plaintiff had no admissible expert opinion 3 that his exposure to chlorine gas caused RADS); Kolesar 412 F. Supp. 2d at 696 (requiring 4 the plaintiff to present expert testimony that his exposure to metam sodium fertilizer caused 5 RADS “because the effects of toxic chemical exposure are complex and not within the ken 6 of ordinary experience”); Byous v. L.M. Scofield Co., No. 3:07-CV-053-JTC, 2009 WL 7 10664903, at *10 (N.D. Ga. Jan. 27, 2009) (“Plaintiffs . . . cannot prove that the Cureseal-S 8 vapors caused [the plaintiff’s] RADS without expert testimony.”); Brookshire Bros., Inc. 9 v. Smith, 176 S.W.3d 30, 36-39 (Tex. App. 2004) (“Expert testimony is particularly 10 necessary in chemical-exposure cases, in which medically complex diseases and causal 11 ambiguities compound the need for expert testimony”). 12 The Court is inclined to agree with the Seventh Circuit’s observation that “a typical 13 layperson does not possess the requisite knowledge to draw a causative line, without the 14 assistance of a medical expert, between a brief encounter with [a toxic] gas and the onset 15 of . . . RADS[,] a disease with which . . . most lay people have no familiarity[.]” Higgins, 16 794 F.3d at 702. The Court therefore is inclined to grant summary judgment on the issue 17 of whether Alsadi’s exposure to H2S caused RADS. Under Arizona law, “where the 18 plaintiffs’ evidence does not establish a causal connection, leaving causation to the jury’s 19 speculation,” the Court should “remove this question from the jury.” Benshoof, 978 F.2d 20 at 476. Without an admissible expert opinion that the H2S exposure caused RADS, any 21 jury award of damages for RADS would be based on causation speculation. But because 22 Intel did not address the cases cited above until its reply brief, the Court will give Plaintiffs 23 an opportunity to address the cases and explain why expert testimony may not be necessary 24 to establish a causal link between the exposure event and Alsadi’s alleged RADS. 25 The Court will require supplemental briefing on an additional issue. The Court 26 concludes above that Plaintiffs do not need an expert to show that Alsadi’s injuries on the 27 night in question and immediately thereafter were caused by the H2S exposure. If, after 28 the supplemental briefing, the Court concludes that Plaintiffs cannot recover for RADS 1 without an expert opinion, what is the extent of damages Plaintiffs can seek at trial? Where 2 does the Court draw the line between injuries for which Plaintiffs can recover without a 3 causation expert and injuries for which such an expert is required? The Court does not 4 merely seek the parties’ logical arguments on this issue, but the governing legal 5 principles.22 6 C. Summary Judgment Conclusion. 7 The Court will deny Intel’s motion for summary judgment on Alsadi’s negligence 8 claim with respect to the issues of duty and breach, and deny the motion in part as to 9 whether Intel caused Alsadi an injury. Given this ruling, summary judgment is not 10 warranted on the derivative claim for loss of consortium. See Doc. 183 at 3; Barnes v. 11 Outlaw, 964 P.2d 484, 486-87 (Ariz. 1998) (loss of consortium is a derivative claim 12 requiring proof of the underlying cause of action). 13 IT IS ORDERED: 14 1. Intel’s motion to limit testimony of Plaintiffs’ rebuttal experts (Doc. 144) is 15 granted. 16 2. Intel’s Daubert motion to exclude opinions of Dr. Garcia (Doc. 145) is 17 granted. Dr. Garcia is precluded from offering his causation opinions and his prognosis 18 opinion that Alsadi is at risk for lung disease and may need a lung transplant in the future. 19 3. Intel’s Daubert motion to exclude opinions of Dr. Landers (Doc. 146) is 20 granted in part and denied in part. Dr. Landers is precluded from offering his causation 21 opinion, but may testify regarding his diagnosis of RADS and Alsadi’s prognosis. 22 23 22 Intel contends that Alsadi’s symptoms were transient (Doc. 199 at 7), but does 24 not explain when the symptoms ceased. Intel instead focuses its causation arguments on Alsadi’s alleged RADS, without addressing what other damages Plaintiffs may recover. 25 Similarly, Plaintiffs argue that there is no dispute that Alsadi was injured as a result of the exposure event, and that the dispute concerns the diagnosis and duration of his injuries. 26 Doc. 195 at 12. But Plaintiffs do not address the extent to which the jury may award damages for Alsadi’s injuries absent expert testimony on causation of RADS. If the Court 27 rules that Plaintiffs cannot recover damages for RADS, it must decide where the line should be drawn between recoverable and unrecoverable damages in light of its Daubert and 28 rebuttal expert rulings. 1 4. Intel’s Daubert motion to exclude the opinions of Dr. Johnson-Arbor 2) (Doc. 147) is granted. 3 5. Intel’s Daubert motion to exclude the opinions of Greg Gerganoff (Doc. 163) 4| is denied. 5 6. Plaintiffs’ motion to strike Intel’s untimely sixth supplemental disclosure 6 | statement under Rule 37(c)(1) (Doc. 200) is denied because the motion is not proper under 7| Local Rule 7.2(m). The other motions to strike (Docs. 154-55, 159-61, 167, 187) are 8 | denied. 9 7. Intel’s motion for summary judgment (Doc. 183) is denied in part as set 10 | forth above. 11 8. The parties shall simultaneously file memoranda, not to exceed seven pages in length, addressing the causation and damages issues described above by 13 | October 14, 2019. 14 Dated this 30th day of September, 2019. 15 ‘ 16 d aud 6, Cater pLhtl 17 David. Campbell 18 Senior United States District Judge 19 20 21 22 23 24 25 26 27 28 26